Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia
Authors:
- Jon HelgestadJHJon Helgestad
- Steen RosthøjSRSteen Rosthøj
- Preben JohansenPJPreben Johansen
- Kim VarmingKVKim Varming
- Erik ØstergaardEØErik Østergaard
- 25 February 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (2) , 224-226
Abstract
Morphological evaluation of early response to chemotherapy and measurement of minimal residual disease by flow cytometry or PCR are being used for evaluation of prognosis and treatment stratification in children with acute lymphoblastic leukaemia (ALL). In a series of 14 consecutive bone marrow investigations from children with precursor B-cell ALL, morphological evaluations of smears and flow cytometric measurements of minimal residual disease in sequentially aspirated small (2 ml) and large (5-10 ml) volumes of bone marrow were compared, at various time points during therapy. The density of nucleated cells was markedly reduced in the large volume aspirate. The percentage of erythroblasts measured by flow cytometry was smaller, indicating dilution with peripheral cells. Similarly, the blast percentage was reduced with 54% in large aspirates, and in four instances with minimal residual disease of >0.1% in the small volume, the level of blasts in the large aspirate was below this limit. The amount of minimal residual disease should be measured in the first 2.5 ml of bone marrow aspirated from one puncture site. The procedure should be performed by experienced and carefully instructed doctors. In large aspirates, minimal residual disease will be underestimated, which may lead to failure to undertake a required intensification of therapy and a lower fraction of high risk patients in the trial.Keywords
This publication has 15 references indexed in Scilit:
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaBlood, 2010
- Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyBlood, 2010
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008Leukemia, 2009
- Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic LeukemiaHematology/Oncology Clinics of North America, 2009
- Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy – results from a single UK centreBritish Journal of Haematology, 2008
- Clinical Trials in Childhood Acute Lymphoblastic Leukemia: A Common Prognostic Classification and a Common Induction Therapy Are Now WarrantedJournal of Pediatric Hematology/Oncology, 2002
- Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological reviewBritish Journal of Haematology, 2001
- Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study groupLeukemia, 2000
- New definition of remission in childhood acute lymphoblastic leukemiaLeukemia, 2000
- Survival in Childhood Acute Lymphocytic Leukemia: Effect of Protocol and Place of TreatmentCancer Investigation, 1983